Merimepodib
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2004 (NCT00088504)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
IMPDH1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1- Mol. weight
- 452.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL304087 ↗
Also known as
- merimepodib
- merimepodib
- merimepodib
- merimepodib
- merimepodib
- mmpd
- mmpd
- n-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester
- vi-21497
- vi-21497
- vx 497
- vx-497
- vx-497
- vx-497
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04410354 | Phase 2 | Jun 30, 2020 | Mayo Clinic, ViralClear Pharmaceuticals, Inc. |
| NCT00088504 | Phase 2 | Jul 1, 2004 | Vertex |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Vertex | For profit | 1 | 1 | 1 | 2004 |
| ViralClear Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1